Introduction
Two years ago, I wrote an article about Teva (NYSE:TEVA). Back then, the price was around $55, and it rose all the way to $69 six months later. Since then, the stock price has plunged all the way to the current price of ~$32. That's the lowest price since 2006. Many investors believe that Teva now offers a buying opportunity, but I am afraid that they were those who thought it was attractive when it traded for $55.
The risks that Teva has to deal with are still here. They have actually grown larger. At the same time, new risks emerged, and the current management is unable to deal with them. There is a huge cloud over Teva, and as an investor, I hate those uncertainties.
The growth opportunities are far from being enough to compete with those risks. Moreover, the company still cannot show any new solid path for growth and expansion. We keep hearing the same music. Growth through acquisitions sounds great, but we just cannot see it.
